| Title: |
The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study |
| Authors: |
Conget, Ignacio; Castaneda, Javier; Petrovski, Goran; Guerci, Bruno; Racault, Anne Sophie; Reznik, Yves; Cohen, Ohad; Runzis, Sarah; De Portu, Simona; Aronson, Ronnie; Petrovski, G.; Reznik, Y.; Kocsis, G.; Lalic, N.; Tildesley, H.; Cohen, O.; Priestman, B. A.; Metzger, M.; Joyce, Carol; Podgorski, G.; Conway, R.; Aronson, R.; Perkins, B.; Kooy, A.; Liebl, A.; Guerci, B.; Bode, B.; Nardacci, E.; Buchs, A.; Harmann Boehm, I.; Ross, S.; Filetti, S.; Yale, J. F.; Conget, I.; Giménez, M.; Distiller, L.; Weinstock, R. S.; Zinger, J.; Prager, R.; Mosinzon, O.; Rose, L.; GIORGINO, Francesco; Alwani, R.; Lieverse, L.; Bolli, G. B.; Moreau, F.; Hanaire, H. |
| Contributors: |
Conget, Ignacio; Castaneda, Javier; Petrovski, Goran; Guerci, Bruno; Racault, Anne Sophie; Reznik, Yve; Cohen, Ohad; Runzis, Sarah; De Portu, Simona; Aronson, Ronnie; Petrovski, G.; Reznik, Y.; Kocsis, G.; Lalic, N.; Tildesley, H.; Cohen, O.; Priestman, B. A.; Metzger, M.; Joyce, Carol; Podgorski, G.; Conway, R.; Aronson, R.; Perkins, B.; Kooy, A.; Liebl, A.; Guerci, B.; Bode, B.; Nardacci, E.; Buchs, A.; Harmann Boehm, I.; Ross, S.; Filetti, S.; Yale, J. F.; Conget, I.; Giménez, M.; Distiller, L.; Weinstock, R. S.; Zinger, J.; Prager, R.; Mosinzon, O.; Rose, L.; Giorgino, Francesco; Alwani, R.; Lieverse, L.; Bolli, G. B.; Moreau, F.; Hanaire, H. |
| Publication Year: |
2016 |
| Collection: |
Università degli Studi di Bari Aldo Moro: CINECA IRIS |
| Subject Terms: |
Endocrinology; Diabetes and Metabolism; Medical Laboratory Technology |
| Description: |
Background: The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. Research Design and Methods: Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and ≤12% (108 mmol/mol) despite insulin doses of 0.7-1.8 U/kg/day via MDI were randomized to CSII (n=168) or continued MDI (n=163). Changes in glucose profiles were evaluated using continuous glucose monitoring data collected over 6-day periods before and 6 months after randomization. Results: After 6 months, reductions in HbA1c levels were significantly greater with CSII (-1.1±1.2% [-12.0±13.1 mmol/mol]) than with MDI (-0.4±1.1% [-4.4±12.0 mmol/mol]) (P180 mg/dL (-12.4%; P=0.0004) and SG >250 mg/dL (-5.5%; P=0.0153), and more time in the SG range of 70-180 mg/dL (12.3%; P=0.0002), with no differences in exposure to SG180 mg/dL were significantly greater with CSII than with MDI after breakfast (-775.9±1,441.2 mg/dL/min vs. -160.7±1,074.1 mg/dL/min; P=0.0015) and after dinner (-731.4±1,580.7 mg/dL/min vs. -71.1±1,083.5 mg/dL/min; P=0.0014). Conclusions: In patients with suboptimally controlled type 2 diabetes, CSII significantly improves selected glucometrics, compared with MDI, without increasing the risk of hypoglycemia. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/26241790; info:eu-repo/semantics/altIdentifier/wos/WOS:000368014600005; volume:18; issue:1; firstpage:22; lastpage:28; numberofpages:7; journal:DIABETES TECHNOLOGY & THERAPEUTICS; https://hdl.handle.net/11586/170426; www.liebertonline.com/dia |
| DOI: |
10.1089/dia.2015.0159 |
| Availability: |
https://hdl.handle.net/11586/170426; https://doi.org/10.1089/dia.2015.0159 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/3.0/it/ |
| Accession Number: |
edsbas.2B02F59C |
| Database: |
BASE |